Recently, Xizang Zhongwei Chengkang Pharmaceutical Co., LTD., a wholly-owned subsidiary of Weixinkang Pharmaceutical, received the Drug Registration Certificate of multivitamin injection (13) (10/3) approved and issued by the State Drug Administration (drug approval number: Sinofin H20234276). According to the relevant national policies and regulations, the acquisition of the "Drug Registration Certificate" is regarded as passing the consistency evaluation.

On July 12-14, CPHI South East Asia 2023 was held at the Queen Sirikit National Convention Center in Bangkok, Thailand. Weixinkang brought core products in the field of apis and preparations to the exhibition, sharing new ideas with exhibitors and customers around the world, seeking new cooperation in the development of pharmaceutical foreign trade, and going to a new journey of internationalization.

Dopamine hydrochloride injection is suitable for shock syndrome caused by myocardial infarction, trauma, endotoxin sepsis, cardiac operation, renal failure, congestive heart failure, etc. Shock can not be corrected after blood volume supplementation, especially oliguria and normal or low peripheral vascular resistance shock. Since this product can increase cardiac output, it is also used for cardiac insufficiency where digitalis and diuretics do not work. Dopamine hydrochloride injection belongs to the "National Basic Medical Insurance, Industrial injury insurance and maternity Insurance drug Catalogue (2022)" class A drugs, "National Essential Drugs Catalogue (2018 edition)" drugs. The reference preparation for this variety is INOVAN® injection, marketed by Concorde 発 Yeast キリン Co., Ltd. in 2.5ml:50mg, 5ml:100mg.

The 16th National Conference on Geriatric Diseases and Nutritional Therapy was successfully held in Beijing from 2 to 4 June, organized by the Geriatric Nutrition Support Group of the Chinese Society for Parenteral and Enteral Nutrition and the China Association for the Promotion of International Exchange in Health Care,

The 86th National Pharmaceutical Trade Fair was held at Qingdao Expo City International Exhibition Center from May 9-11, 2023. As an influential professional event in the field of pharmaceutical preparations and health in China, this year's fair brought together more than 2,000 high-quality enterprises, with products covering more than 10 categories, including chemical drugs, biological drugs and OTC drugs, etc. Weixinkang exhibited 16 of its own products at this event.

he 11th National Conference on Oncology Nutrition, hosted by the Oncology Nutrition Committee of the China Anti-Cancer Association and organized by Beijing Jiatan Hospital of Capital Medical University, was held in Beijing from April 21 to 23.

From 20 to 22 April, the 9th National Congress of Pediatric Critical Care Physicians of the China Medical Association (CMCAP) was held at the Beiyuan Hotel in Beijing, hosted by the CMCAP and the Pediatric Critical Care Physicians Branch of the CMCAP.

On the evening of January 18, 2023, the National Health Insurance Bureau and the Ministry of Human Resources Social Security issued the Notice on the Issuance of the National Drug Catalogue for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (2022)> (Health Insurance Fa [2023] No. 5), in which Tibet Weixinkang Pharmaceutical Co.,Ltd. (hereinafter referred to as "the Company") has been included in the 2022 edition of the National Health Insurance Catalogue through medical insurance negotiations. This version of the National Health Insurance Catalogue will be officially implemented from March 1, 2023.